Hetero Labs Limited

Hetero Labs Limited is a vertically integrated pharmaceutical company headquartered in Hyderabad, Telangana, India, founded on March 10, 1989. It serves as the flagship company of the larger Hetero Group, which was established in 1993. As a privately held public limited company, Hetero Labs Limited reported a revenue of approximately ₹16,500 Crore (around $2 billion USD) for the financial year ending March 31, 2025, and had 7,280 employees as of August 1, 2025. The broader Hetero Group has a global presence in over 140 countries and operates more than 36 manufacturing facilities worldwide.

The company specializes in the research, development, manufacturing, and marketing of high-quality chemical and biologic medicines. Its key business areas include Active Pharmaceutical Ingredients (APIs), generic formulations, biosimilars, and custom pharmaceutical services. Hetero is notably one of the world's largest producers of anti-retroviral (ARV) drugs, catering to approximately 40% of the global demand for HIV/AIDS treatment. Their extensive product portfolio spans over 20 therapeutic areas, including antineoplastics, cardiovascular drugs, antidepressants, and antivirals such as generic versions of Remdesivir and Favipiravir for COVID-19.

In terms of patent litigation, Hetero Labs Limited operates as an operating company that defends against patent infringement claims, a common posture for generic pharmaceutical manufacturers. The company has been tracked as a defendant in one patent litigation case and has no recorded appearances as a plaintiff. This single case, Otsuka Pharmaceutical Co., Ltd. v. Hetero USA Inc. et al., was filed in the District of Delaware in 2014, involving its group company Hetero USA Inc. This type of litigation is typical for generic drug companies challenging existing drug patents to bring more affordable medicines to market.